This brand name is authorized in Australia, Austria, Croatia, Estonia, France, Hong Kong SAR China, Ireland, Italy, Japan, Lithuania, Netherlands, Nigeria, Poland, Romania, Singapore, South Africa, Tunisia, Turkey.
The drug RYZODEG contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
54Q18076QB - INSULIN DEGLUDEC
|
|
Insulin degludec binds specifically to the human insulin receptor and results in the same pharmacological effects as human insulin. The blood glucose-lowering effect of insulin is due to the facilitated uptake of glucose following the binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. |
|
2
|
UNII
D933668QVX - INSULIN ASPART
|
|
The blood glucose lowering effect of insulin aspart is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. Insulin aspart produces a more rapid onset of action compared to soluble human insulin, together with a lower glucose concentration, as assessed within the first four hours after a meal. Insulin aspart has a shorter duration of action compared to soluble human insulin after subcutaneous injection. |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| RYZODEG Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| A10AD06 | A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10A Insulins and analogues → A10AD Insulins and analogues for injection, intermediate-acting combined with fast-acting | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| AU | Pharmaceutical Benefits Scheme | 11417X, 11426J |
| EE | Ravimiamet | 1607284, 1607295, 1607307, 1607318, 1607329, 1716184 |
| FR | Base de données publique des médicaments | 62434021, 64363612 |
| HK | Department of Health Drug Office | 62701 |
| IT | Agenzia del Farmaco | 042656013, 042656025, 042656037, 042656049, 042656052, 042656064, 042656076 |
| JP | 医薬品医療機器総合機構 | 2492500G1025 |
| LT | Valstybinė vaistų kontrolės tarnyba | 1069114, 1069115, 1069116, 1071811, 1071812, 1088336, 1088339 |
| NG | Registered Drug Product Database | A6-0489 |
| NL | Z-Index G-Standaard, PRK | 135518 |
| PL | Rejestru Produktów Leczniczych | 100316295 |
| RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | W67111001, W67111002, W67111003, W67111004, W67111005, W67112001, W67112002 |
| SG | Health Sciences Authority | 15706P |
| TN | Direction de la Pharmacie et du Médicament | 5993141 |
| TR | İlaç ve Tıbbi Cihaz Kurumu | 8699676951000, 8699676951017, 8699676951024, 8699676951031, 8699676951048, 8699676951055 |
| ZA | Health Products Regulatory Authority | 47/21.1/0165 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.